National decision-making for the introduction of new vaccines: A systematic review, 2010-2020.

Morgane Donadel, Maria Susana Panero, Lynnette Ametewee, Abigail M Shefer
Author Information
  1. Morgane Donadel: Global Immunization Division, Centers for Disease Control and Prevention, Atlanta, GA, USA. Electronic address: mxi4@cdc.gov.
  2. Maria Susana Panero: Global Immunization Division, Centers for Disease Control and Prevention, Atlanta, GA, USA.
  3. Lynnette Ametewee: Global Immunization Division, Centers for Disease Control and Prevention, Atlanta, GA, USA; Department of Population Health Sciences, School of Public Health, Georgia State University, Atlanta, GA, USA.
  4. Abigail M Shefer: Global Immunization Division, Centers for Disease Control and Prevention, Atlanta, GA, USA.

Abstract

BACKGROUND: Competing priorities make using a transparent and evidence-based approach important when deciding to recommend new vaccines. We conducted a literature review to document the processes and frameworks for national decision-making on new vaccine introductions and explored which key features have evolved since 2010.
METHODS: We searched literature published on policymaking related to vaccine introduction from March 2010 to August 2020 in six databases. We screened articles for eligibility with the following exclusion criteria: non-human or hypothetical vaccines, the sole focus on economic evaluation or decision to adopt rather than policy decision-making. We employed nine broad categories of criteria from the 2012 review for categorization and abstracted data on the country, income level, vaccine, and other relevant criteria.
RESULTS: Of the 3808 unique references screened, 116 met eligibility criteria and were classified as: a) framework of vaccine adoption decision-making (27), b) studies that analyse empirical data on or examples of vaccine adoption decision-making (45), c) theoretical and empirical articles that provide insights into the vaccine policymaking process (44 + 17 already included in the previous categories). Commonly reported criteria for decision-making were the burden of disease; vaccine efficacy/effectiveness, safety; impact on health and non-health outcomes; economic evaluation and cost-effectiveness of alternative interventions. Programmatic and acceptability aspects were not as often considered. Most (50; 82%) of the 61 articles describing the process of vaccine introduction policymaking highlighted the role of country, regional, or global evidence-informed recommendations and a robust national governance as enabling factors for vaccine adoption.
CONCLUSIONS: The literature on vaccine adoption decision-making has expanded since 2010. We found that policymakers and expert advisory committee members (e.g., National Immunization Technical Advisory Group [NITAG]) increasingly value the interventions based on economic evaluations. The results of this review could guide discussions on evidence-informed immunization decision-making among country, sub-regional, and regional stakeholders.

Keywords

References

  1. Vaccine. 2020 Jul 14;38(33):5109-5113 [PMID: 32563604]
  2. Vaccine. 2010 Apr 19;28 Suppl 1:A88-90 [PMID: 20413005]
  3. J Infect Dis. 2017 Jul 1;216(suppl_1):S130-S136 [PMID: 28838156]
  4. Vaccine. 2019 Jul 26;37(32):4646-4650 [PMID: 31266668]
  5. Vaccine. 2012 Mar 28;30(15):2588-93 [PMID: 22330125]
  6. Vaccine. 2015 Feb 25;33(9):1206-17 [PMID: 25533328]
  7. Vaccine. 2015 Jun 8;33 Suppl 2:B52-4 [PMID: 26022569]
  8. Vaccine. 2012 Sep 7;30 Suppl 3:C79-86 [PMID: 22939027]
  9. Vaccine. 2016 Jun 17;34(29):3420-6 [PMID: 26704259]
  10. Health Policy Plan. 2012 May;27 Suppl 2:ii62-76 [PMID: 21733989]
  11. Hum Vaccin. 2010 Dec;6(12):1021-4 [PMID: 21150269]
  12. Clin Microbiol Infect. 2013 Dec;19(12):1096-105 [PMID: 23957860]
  13. Vaccine. 2015 Jan 29;33(5):588-95 [PMID: 25545597]
  14. BMC Public Health. 2016 Aug 02;16:684 [PMID: 27484123]
  15. BMC Med. 2011 May 12;9:55 [PMID: 21569407]
  16. Int J Health Policy Manag. 2017 Apr 08;6(12):707-720 [PMID: 29172378]
  17. Hum Vaccin. 2011 Sep;7(9):900-4 [PMID: 21865880]
  18. Health Policy Plan. 2012 May;27 Suppl 2:ii1-4 [PMID: 22513728]
  19. Vaccine. 2011 Mar 16;29(13):2371-80 [PMID: 21159324]
  20. Hum Vaccin Immunother. 2019;15(2):440-443 [PMID: 30296194]
  21. J Infect Dis. 2017 Jul 1;216(suppl_1):S109-S113 [PMID: 28838176]
  22. J Infect. 2014 Jan;68 Suppl 1:S100-7 [PMID: 24206897]
  23. PLoS Med. 2009 Jul 21;6(7):e1000100 [PMID: 19621070]
  24. Hum Vaccin Immunother. 2020 Jul 2;16(7):1728-1737 [PMID: 32574124]
  25. Vaccine. 2013 Aug 20;31(37):3826-33 [PMID: 23357196]
  26. Vaccine. 2013 Dec 9;31(51):6046-9 [PMID: 23968768]
  27. Health Res Policy Syst. 2013 Aug 08;11:30 [PMID: 23924162]
  28. Rev Chilena Infectol. 2014 Oct;31(5):590-603 [PMID: 25491459]
  29. PLoS Negl Trop Dis. 2013;7(3):e2127 [PMID: 23516658]
  30. Cad Saude Publica. 2010 May;26(5):900-8 [PMID: 20563390]
  31. Vaccine. 2013 Apr 18;31 Suppl 2:B81-96 [PMID: 23598496]
  32. Vaccine. 2015 May 7;33 Suppl 1:A28-33 [PMID: 25919170]
  33. Sci Transl Med. 2016 Jun 29;8(345):345ps14 [PMID: 27358496]
  34. Salud Publica Mex. 2010 May-Jun;52(3):226-33 [PMID: 20485886]
  35. Health Policy Plan. 2012 May;27 Suppl 2:ii50-61 [PMID: 22513733]
  36. PLoS Med. 2010 Mar 16;7(3):e1000249 [PMID: 20305714]
  37. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2013 Jul;56(7):957-84 [PMID: 23807405]
  38. Sex Health. 2010 Sep;7(3):262-70 [PMID: 20719213]
  39. Int J Health Policy Manag. 2020 Oct 01;9(10):439-447 [PMID: 32610741]
  40. Vaccine. 2013 Jul 02;31 Suppl 3:C114-22 [PMID: 23777684]
  41. Vaccine. 2012 Sep 7;30 Suppl 3:C9-13 [PMID: 22939028]
  42. Vaccine. 2016 Jul 12;34(32):3697-701 [PMID: 27055022]
  43. Vaccine. 2010 Nov 16;28(49):7723-30 [PMID: 20933042]
  44. Vaccine. 2013 Jul 02;31 Suppl 3:C88-93 [PMID: 23777698]
  45. Vaccine. 2010 Apr 19;28 Suppl 1:A26-30 [PMID: 20412992]
  46. PLoS Negl Trop Dis. 2014 Jul 31;8(7):e3009 [PMID: 25077478]
  47. Milbank Q. 2016 Mar;94(1):109-25 [PMID: 26994711]
  48. Vaccine. 2018 Aug 6;36(32 Pt B):4939-4943 [PMID: 30037484]
  49. BMC Med. 2013 Mar 14;11:71 [PMID: 23496946]
  50. Vaccine. 2011 Apr 12;29(17):3149-54 [PMID: 21354249]
  51. Expert Rev Vaccines. 2016 Oct;15(10):1295-304 [PMID: 26982434]
  52. Expert Rev Vaccines. 2019 Jun;18(6):575-585 [PMID: 31216187]
  53. BMC Public Health. 2019 Jun 20;19(1):781 [PMID: 31221112]
  54. Vaccine. 2012 Sep 7;30 Suppl 3:C21-7 [PMID: 22939016]
  55. Vaccine. 2014 Mar 20;32(14):1610-5 [PMID: 24606638]
  56. Vaccine. 2018 Sep 5;36(37):5536-5543 [PMID: 30076103]
  57. Vaccine. 2014 Dec 12;32(52):7033-6 [PMID: 24856784]
  58. Health Policy. 2014 Mar;115(1):82-91 [PMID: 24444703]
  59. Expert Rev Vaccines. 2011 Sep;10(9):1265-70 [PMID: 21919616]
  60. Rev Esp Salud Publica. 2016 Mar 08;90:E2 [PMID: 26960253]
  61. Soc Sci Med. 2013 Apr;83:1-9 [PMID: 23465198]
  62. Health Policy. 2019 Mar;123(3):260-266 [PMID: 30219371]
  63. Vaccine. 2017 Mar 7;35(10):1380-1389 [PMID: 28253995]
  64. PLoS One. 2013 Jul 16;8(7):e70003 [PMID: 23875015]
  65. Korean J Pediatr. 2012 Jan;55(1):1-5 [PMID: 22359523]
  66. Vaccine. 2010 Apr 26;28(19):3379-84 [PMID: 20197141]
  67. Vaccine. 2015 Jun 8;33 Suppl 2:B34-9 [PMID: 26022565]
  68. Soc Sci Med. 2010 Oct;71(7):1349-1356 [PMID: 20692756]
  69. Lancet Infect Dis. 2012 Aug;12(8):627-34 [PMID: 22445354]
  70. Health Policy Plan. 2012 May;27 Suppl 2:ii39-49 [PMID: 22513731]
  71. Rev Mal Respir. 2019 Nov;36(9):1038-1046 [PMID: 31521428]
  72. Vaccine. 2019 Jan 14;37(3):464-472 [PMID: 30502070]
  73. Vaccine. 2013 Jul 02;31 Suppl 3:C8-9 [PMID: 23777696]
  74. Malar J. 2016 Mar 08;15:143 [PMID: 26956944]
  75. Vaccine. 2015 Jan 9;33(3):405-14 [PMID: 25446820]
  76. Indian J Med Res. 2010 May;131:617-28 [PMID: 20516532]
  77. Vaccine. 2014 Apr 1;32(16):1778-80 [PMID: 24530935]
  78. Vaccine. 2010 Oct 8;28(43):7123-9 [PMID: 20659515]
  79. Vaccine. 2012 Sep 7;30 Suppl 3:C35-7 [PMID: 22939019]
  80. Vaccine. 2012 Nov 20;30 Suppl 5:F192-200 [PMID: 23199963]
  81. Vaccine. 2014 Aug 11;32 Suppl 1:A171-8 [PMID: 25091672]
  82. Expert Rev Vaccines. 2011 Feb;10(2):163-73 [PMID: 21332266]
  83. Vaccine. 2012 Sep 7;30 Suppl 3:C3-8 [PMID: 22939018]
  84. Can J Infect Dis Med Microbiol. 2015 Jul-Aug;26(4):183-90 [PMID: 26361485]
  85. Soc Sci Med. 2010 Sep;71(6):1049-55 [PMID: 20667640]
  86. J Health Popul Nutr. 2013 Jun;31(2):211-7 [PMID: 23930339]
  87. Vaccine. 2014 Oct 21;32(46):6049-53 [PMID: 25239482]
  88. Curr Opin Infect Dis. 2010 Jun;23(3):236-41 [PMID: 20407316]
  89. Vaccine. 2012 Sep 7;30 Suppl 3:C66-71 [PMID: 22939025]
  90. Gynecol Obstet Invest. 2010;70(4):224-32 [PMID: 21051840]
  91. Vaccine. 2017 May 25;35(23):3007-3011 [PMID: 28456526]
  92. Vaccine. 2010 Apr 19;28 Suppl 1:A18-25 [PMID: 20412991]
  93. Front Public Health. 2018 May 14;6:131 [PMID: 29868539]
  94. Health Policy Plan. 2012 May;27 Suppl 2:ii5-16 [PMID: 22513732]
  95. Vaccine. 2013 Jul 02;31 Suppl 3:C10-1 [PMID: 23777682]
  96. BMC Public Health. 2015 Apr 10;15:356 [PMID: 25881178]
  97. Vaccine. 2011 Jan 17;29(4):624-8 [PMID: 21081178]
  98. Arch Dis Child. 2020 Mar;105(3):216-222 [PMID: 31302603]
  99. Vaccine. 2016 Jun 30;34(31):3592-7 [PMID: 27195757]
  100. Vaccine. 2015 May 7;33 Suppl 1:A21-7 [PMID: 25919164]
  101. J Infect Dis. 2014 Nov 1;210 Suppl 1:S143-51 [PMID: 25316829]
  102. Vaccine. 2011 Nov 15;29(49):9171-6 [PMID: 21839794]
  103. J Comp Eff Res. 2017 May;6(3):195-204 [PMID: 28485691]
  104. Vaccine. 2010 Apr 1;28(16):2841-5 [PMID: 20153796]
  105. Vaccine. 2013 Apr 18;31 Suppl 2:B122-8 [PMID: 23598473]
  106. Lancet. 2011 Jul 30;378(9789):439-48 [PMID: 21664676]
  107. Vaccine. 2019 Sep 16;37(39):5817-5824 [PMID: 31474519]
  108. PLoS One. 2010 Nov 02;5(11):e13802 [PMID: 21072192]
  109. Turk J Pediatr. 2010 Nov-Dec;52(6):563-9 [PMID: 21428186]
  110. Vaccine. 2016 Mar 8;34(11):1325-30 [PMID: 26859237]
  111. Vaccine. 2013 Jul 02;31 Suppl 3:C6-7 [PMID: 23777693]
  112. Vaccine. 2012 Dec 17;31(1):12-9 [PMID: 22391401]
  113. Vaccine. 2014 Aug 11;32 Suppl 1:A162-70 [PMID: 25091671]
  114. Vaccine. 2013 Jul 02;31 Suppl 3:C4-5 [PMID: 23777690]
  115. Vaccine. 2015 Jun 8;33 Suppl 2:B29-33 [PMID: 26022563]
  116. Philos Trans R Soc Lond B Biol Sci. 2011 Oct 12;366(1579):2827-32 [PMID: 21893547]
  117. Health Policy Plan. 2012 May;27 Suppl 2:ii27-38 [PMID: 22513730]
  118. Vaccine. 2020 Feb 29;38 Suppl 1:A157-A159 [PMID: 31266672]
  119. Vaccine. 2014 Jul 7;32(32):4089-96 [PMID: 24837537]
  120. Vaccine. 2011 Jan 29;29(5):1099-106 [PMID: 21144916]
  121. Clin Infect Dis. 2020 Jul 29;71(Suppl 2):S172-S178 [PMID: 32725235]
  122. Health Policy Plan. 2012 May;27 Suppl 2:ii17-26 [PMID: 22513729]
  123. Health Policy Plan. 2016 Oct;31(8):1079-88 [PMID: 27107293]
  124. BMC Public Health. 2020 Aug 8;20(1):1216 [PMID: 32770996]

Grants

  1. CC999999/Intramural CDC HHS

MeSH Term

Health Policy
Immunization
Immunization Programs
Vaccination
Vaccines

Chemicals

Vaccines

Word Cloud

Created with Highcharts 10.0.0vaccinedecision-makingreviewcriteriaadoptionnewliterature2010policymakingintroductionarticleseconomiccountryvaccinesnationalsincescreenedeligibilityevaluationpolicycategoriesdataempiricalprocessinterventionsregionalevidence-informedNationalImmunizationBACKGROUND:Competingprioritiesmakeusingtransparentevidence-basedapproachimportantdecidingrecommendconducteddocumentprocessesframeworksintroductionsexploredkeyfeaturesevolvedMETHODS:searchedpublishedrelatedMarchAugust2020sixdatabasesfollowingexclusioncriteria:non-humanhypotheticalsolefocusdecisionadoptratheremployedninebroad2012categorizationabstractedincomelevelrelevantRESULTS:3808uniquereferences116metclassifiedas:framework27bstudiesanalyseexamples45ctheoreticalprovideinsights44 + 17alreadyincludedpreviousCommonlyreportedburdendiseaseefficacy/effectivenesssafetyimpacthealthnon-healthoutcomescost-effectivenessalternativeProgrammaticacceptabilityaspectsoftenconsidered5082%61describinghighlightedroleglobalrecommendationsrobustgovernanceenablingfactorsCONCLUSIONS:expandedfoundpolicymakersexpertadvisorycommitteemembersegTechnicalAdvisoryGroup[NITAG]increasinglyvaluebasedevaluationsresultsguidediscussionsimmunizationamongsub-regionalstakeholdersvaccines:systematic2010-2020Evidence-basedHealthsystemstrengtheningprogramsInfectiousdiseasesSystematicVaccine

Similar Articles

Cited By